WebNov 11, 2024 · A reduction in LDL-C of almost 50% was seen in the phase II study of nine patients with HoFH and was further confirmed in the ELIPSE HoFH phase III trial, whereby a 47% reduction in LDL-C and a decrease in TG and apo B of 55 and 41%, respectively, was seen in those receiving evinacumab versus placebo [40••, 41].

Evinacumab: First Approval SpringerLink

WebAug 19, 2024 · The trial included a run-in period of up to 8 weeks for patients who did not … WebJan 7, 2024 · The approvals were based on results from the Phase 3 ELIPSE HoFH trial, which was published in the NEJM in August 2024. The generic name for Evkeeza in its approved U.S. indications is evinacumab-dgnb, with dgnb the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry … ar操作界面

Full ELIPSE HoFH Results Detail Effects of Evinacumab

WebMay 18, 2024 · Based on the results of the phase III ELIPSE HoFH trial, evinacumab … WebAug 14, 2024 · In the ELIPSE HoFH trial, patients with HoFH (N=65) were randomized to receive evinacumab intravenously (n=43) every 4 weeks or placebo (n=22); patients in the evinacumab treatment group were on ... WebIn the ELIPSE-HoFH trial, the investigators randomly assigned, in a 2:1 ratio, 65 patients with diagnosis of HoFH who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight; n=43) every 4 weeks or placebo (n=22). ar文旅解决方案